Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

CGON

Cg Oncology Inc.

Jun 03 • 04:00PM ET

36.02

Dollar change +3.44
Percentage change 10.56	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IWM VBR VXF IWN VTWO SCHA IWO ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	38.91%	Shs Outstand	66.64M	Perf Week	10.12%
Market Cap	2.40B	Forward P/E	-	EPS next Y	-1.89	Insider Trans	2.64%	Shs Float	40.71M	Perf Month	-8.81%
Income	-	PEG	-	EPS next Q	-0.37	Inst Own	43.78%	Short Float	6.92%	Perf Quarter	-16.41%
Sales	-	P/S	-	EPS this Y	-40.98%	Inst Trans	-	Short Ratio	4.04	Perf Half Y	-
Book/sh	8.54	P/B	4.22	EPS next Y	-19.42%	ROA	-	Short Interest	2.82M	Perf Year	-
Cash/sh	8.50	P/C	4.24	EPS next 5Y	-	ROE	-	52W Range	25.77 - 50.23	Perf YTD	-3.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-28.29%	Beta	-
Dividend TTM	-	Quick Ratio	57.95	Sales past 5Y	-45.67%	Gross Margin	-	52W Low	39.77%	ATR (14)	3.10
Dividend Ex-Date	-	Current Ratio	57.95	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	57.03	Volatility	8.39% 11.55%
Employees	61	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	68.20
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-	Payout	-	Rel Volume	1.10	Prev Close	32.58
Sales Surprise	217.34%	EPS Surprise	-15.38%	Sales Q/Q	-	Earnings	May 09 BMO	Avg Volume	698.35K	Price	36.02
SMA20	15.76%	SMA50	0.47%	SMA200	-5.22%	Trades		Volume	770,887	Change	10.56%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-20-24	Initiated	Morgan Stanley	Overweight	$55
Feb-20-24	Initiated	Goldman	Neutral	$42
Feb-20-24	Initiated	Cantor Fitzgerald	Overweight	$75
Feb-14-24	Initiated	H.C. Wainwright	Buy	$75

May-24-24 08:00AM	CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting (GlobeNewswire) +9.07%
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 01:54PM	CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 (InvestorPlace) -7.43%
08:00AM	CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-03-24 11:23AM	Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (GlobeNewswire) -8.18%
08:00AM	Loading…
Apr-26-24 08:00AM	CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 (GlobeNewswire) +13.26%
Apr-24-24 10:00AM	CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire)
Apr-11-24 10:02PM	20 Countries with the Most Domestically Listed Companies in the World (Insider Monkey)
Mar-28-24 08:00AM	CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting (GlobeNewswire) +7.07%
Feb-27-24 08:00AM	CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer (GlobeNewswire)
Jan-30-24 07:00AM	CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire)
Jan-26-24 04:20PM	In Bad News for IPO Market, BrightSpring Closes Below Offering Price (The Wall Street Journal) -5.76%
Jan-24-24 07:10PM	CG Oncology Announces Pricing of Upsized Initial Public Offering (Business Wire)

CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. It offers cretostimogene, a product initially in clinical development for the treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC). The company was founded by Alex Yeung and Paul A. DeRidder on September 24, 2010 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Decheng Capital Global Life Sc	10% Owner	Jan 29 '24	Buy	19.00	400,000	7,600,000	400,000	Jan 31 04:17 PM
Song Hong Fang	Director	Jan 29 '24	Buy	19.00	263,157	4,999,983	613,928	Jan 31 04:30 PM
Roche Corleen M.	CFO & Secretary	Jan 29 '24	Buy	19.00	2,000	38,000	2,000	Jan 31 04:30 PM
Kasturi Vijay	Chief Medical Officer	Jan 29 '24	Buy	19.00	1,315	24,985	1,315	Jan 31 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGON

Cg Oncology Inc.

Upgrade your FINVIZ experience